Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene

pX330.puro Citations (1)

Originally described in: HuR (ELAVL1) silencing sensitizes triple-negative breast cancer to glutaminase-targeted therapy
Sandra Martha Gomes Dias Unpublished

Articles Citing pX330.puro

Articles
Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients. Qiao X, van der Zanden SY, Li X, Tan M, Zhang Y, Song JY, van Gelder MA, Hamoen FL, Janssen L, Zuur CL, Pang B, van Tellingen O, Li J, Neefjes J. Mol Cancer. 2024 Jun 4;23(1):120. doi: 10.1186/s12943-024-02034-7. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.